×

RNS Number : 3920E

Crimson Tide PLC

18 July 2016

 

Crimson Tide PLC

 

("Crimson Tide" or the 'Company')

 

Crimson Tide selected by large UK retailer

 

Crimson Tide (TIDE), the AIM-quoted provider of mpro5 – Smart Mobility as a Service, has won a contract with a large UK retailer whereby mpro5 will be used to monitor store safety, cleanliness and security. The initial contract value for a pilot period is approximately £200,000. Subject to a successful pilot period, the retailer will deploy mpro5 for a 48-month term with a considerably higher value.

The roll-out involves implementing the mobility platform to enable the scheduling of regular cleaning, reactive cleaning and incident capture as well as providing dynamic audits and bespoke management dashboards.  Jobs are scheduled via the mpro5 website, and are then pushed to a mobile device.  Remote users monitor business workflows and capture pertinent information which is then automatically synchronised with the cloud to the central repository.  Real time audit dashboards and reports are securely shared to relevant management.

mpro5 provides barcode scanning and cloud-based synchronisation services via Microsoft Azure, renowned for its reliability, scalability and security.  This enables real-time information upload, quick verifications and multi-way data request transmittals.

This customer stands to benefit from improvements in reporting and visibility, quality auditing, health and safety, financial savings, consumer satisfaction and overall efficiency and productivity. mpro5 provides additional protection against any spurious 'slip-and-trip' claims in large, multi-site retail environments.

Barrie Whipp, Executive Chairman of Crimson Tide, said: "Our team has worked diligently in providing a solid business case to our client, which has resulted in this success.  I am delighted we are able to assist this household-name customer in transforming its business and ultimately providing true ROI using mpro5."

 

‐ ends ‐

 

For further information:

 

Crimson Tide plc

 

Barrie Whipp                                                                                       01892 542 444

Steve Goodwin

 

WH Ireland

 

James Joyce /James Bavister                                                             020 7220 1666

Allerton Communications

Peter Curtain                                                                                        020 3137 2500

peter.curtain@allertoncomms.co.uk 

 

Notes to editors

Founded in 1996 and quoted on AIM since 2006, Crimson Tide plc is the provider of mpro5 – Smart Mobility as a Service (SMaaS).  mpro5 is delivered on smartphones, tablets and PDAs, and enables companies to transform their businesses and strengthen their workforces.

Crimson Tide offers a global service, working with some of the world's leading companies, tailoring mpro5 to suit customer needs. Developed over 10 years by its world-class team, mpro5 is the smart choice for organisations large and small that want to improve productivity and save money.

mpro5 is a platform-agnostic mobility suite fully hosted on Microsoft Azure, so customers are quickly up and running and the service is scalable and robust. It is provided on subscription, so clients can immediately see a return on their investment.

mpro5 not only helps people improve their day-to-day working methods while saving employers money, it also saves lives, by enabling haemophilia patients to verify the safety of their medication before use. mpro5 clients come from a diverse range of industries allowing the Company to  listen, share and find the best solution for all mobility needs.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCGGUPCMUPQPUM

Close

×

RNS Number : 3908E

Transense Technologies PLC

18 July 2016

 

18 July 2016

 

Transense Technologies Plc

("Transense" or "the Company")

Licence Agreement with GE

 

Transense Technologies Plc (AIM: TRT), the provider of sensor systems for the transportation and industrial markets, is pleased to announce that it has signed a licencing agreement (the "Agreement") with General Electric Company ("GE") for the use of Transense's patented, wireless, passive Surface Acoustic Wave (SAW) technology in certain specific torque applications.

The Agreement, which is non-exclusive, provides for a non-refundable payment to Transense of US$500,000 on signing.  GE will pay a further non-refundable payment to Transense of US$250,000, subject to the Company's SAW technology passing various tests to be conducted by GE.  Should GE not make this further payment by 30 June 2017, the licence will terminate. In addition, GE will pay a perpetual sales royalty to the Company in respect of each unit using the technology.

Graham Storey, CEO of Transense Technologies, said:  "The signing of this licensing agreement with GE is a very significant development for Transense.  Having worked closely with GE since the signing of the memorandum of understanding a year ago, we are very pleased that they have recognised the value of incorporating our SAW technology in certain of their products and are making this commitment.  As the licence to GE is both non-exclusive and is valid for only a relatively narrow field of use it clearly benchmarks the overall value of the Company's IP portfolio. We continue to work with other potential partners to deploy our SAW technology in the commercial environment."

 

For further information please visit www.transense.co.uk or contact:

 

Transense Technologies Plc Graham Storey, Chief Executive	Tel: +44 (0) 1869 238380
finnCap Ed Frisby, Giles Rolls (Corporate Finance) Tony Quirke, Alice Lane (Corporate Broking)	Tel: +44 (0) 20 7220 0500
IFC Advisory Tim Metcalfe, Graham Herring, Heather Armstrong	Tel: +44 (0) 20 3053 8671

 

 

 

 

About GE

GE (NYSE: GE) is the world's Digital Industrial Company, transforming industry with software-defined machines and solutions that are connected, responsive and predictive. GE is organized around a global exchange of knowledge, the "GE Store" through which each business shares and accesses the same technology, markets, structure and intellect. Each invention further fuels innovation and application across our industrial sectors. With people, services, technology and scale, GE delivers better outcomes for customers by speaking the language of industry. www.ge.com.

 

 

About Transense Technologies

Based in Oxfordshire, UK, Transense has developed patent-protected sensor systems and supporting technology for use in a variety of diverse high growth markets. Transense's Surface Acoustic Wave (SAW), wireless, battery-less, sensor systems offer significant advantages over legacy wireless sensor systems. Transense is targeting the transport and mining industries, and the global torque, temperature and pressure sensing markets, via its trading divisions, Translogik and SAWSense.

Transense's shares are admitted to trading on AIM, a market operated by the London Stock Exchange (AIM: TRT).

www.transense.co.uk

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

AGRSFDFAWFMSEDW

Close

×

RNS Number : 1316E

Crimson Tide PLC

14 July 2016

 

Crimson Tide PLC

 

("Crimson Tide" or the 'Company')

 

Crimson Tide selected for pharmaceutical verification pilot

 

Crimson Tide (TIDE), the AIM-quoted provider of mpro5 – Smart Mobility as a Service, has won a contract for the initial stage of a significant healthcare pilot project in Asia for the serialisation and verification of pharmaceutical products. The pilot project is being implemented under the auspices of the Asia Pacific Economic Cooperation (APEC) Life Sciences Innovation Forum (LSIF), Committee on Trade and Investment (CTI) and Business Advisory Council (ABAC).

 

Selected by a consortium of pharma organisations, the technology platform for the demonstration phase of the pilot project will leverage mpro5 to scan pharmaceutical products, generating an anonymous verification request to the product's manufacturer.   The pilot project seeks to demonstrate for the first time the ability to verify serialised pharmaceutical products from various scan locations to source data stored in distributed databases using global data standards.  The pilot also seeks to promote harmonisation by demonstrating the ability to use a single or reproducible data gateway in multiple countries.

 

mpro5 provides barcode scanning and cloud-based synchronisation services via Microsoft Azure, renowned for its reliability, scalability and security.  This enables real-time information upload, quick verifications and multi-way data request transmittals.

 

Barrie Whipp, Executive Chairman of Crimson Tide, said: "The global impact of drug serialisation and verification cannot be underestimated. I am delighted that we have been chosen to help in this pilot project in Asia, as it opens up significant opportunities in the pharma world."

 

‐ ends ‐

 

For further information:

 

Crimson Tide plc

 

Barrie Whipp                                                                                       01892 542 444

Steve Goodwin

 

WH Ireland

 

James Joyce /James Bavister                                                             020 7220 1666

Allerton Communications

Peter Curtain                                                                                        020 3137 2500

peter.curtain@allertoncomms.co.uk 

 

Notes to editors

Founded in 1996 and quoted on AIM since 2006, Crimson Tide plc is the provider of mpro5 – Smart Mobility as a Service (SMaaS).  mpro5 is delivered on smartphones, tablets and PDAs, and enables companies to transform their businesses and strengthen their workforces.

Crimson Tide offers a global service, working with some of the world's leading companies, tailoring mpro5 to suit customer needs. Developed over 10 years by its world-class team, mpro5 is the smart choice for organisations large and small that want to improve productivity and save money.

mpro5 is a platform-agnostic mobility suite fully hosted on Microsoft Azure, so customers are quickly up and running and the service is scalable and robust. It is provided on subscription, so clients can immediately see a return on their investment.

mpro5 not only helps people improve their day-to-day working methods while saving employers money, it also saves lives, by enabling haemophilia patients to verify the safety of their medication before use. mpro5 clients come from a diverse range of industries allowing the Company to  listen, share and find the best solution for all mobility needs.

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

CNTEAPXDFFLKEFF

Close

×

RNS Number : 9675D

Vela Technologies PLC

12 July 2016

 

12 July 2016

 

Vela Technologies plc

 

("Vela" or the "Company")

 

Proactive interview

The Board of Vela (AIM: VELA), the investing company focused on early-stage and pre-IPO disruptive technology investments, is pleased to provide an opportunity to watch a video interview Proactive Investors recently conducted with Antony Laiker. The video interview, along with an accompany written editorial, can be accessed on Proactive Investor's website at the following address:

http://www.proactiveinvestors.co.uk/companies/stocktube/5264/vela-technologies-looking-for-the-game-changers-says-ceo-5264.html.

 

For further information, please contact:

Vela Technologies plc   Brent Fitzpatrick, Non-Executive Chairman Antony Laiker, Director       Tel: +44 (0) 7802 262 443   Allenby Capital Limited (Nominated Adviser)   Nick Athanas/Katrina Perez   Smaller Company Capital Limited (Broker) Rupert Williams/Jeremy Woodgate       Tel: +44 (0) 20 3328 5656       Tel: +44 (0) 20 3651 2910

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRAAKBDBBBKDFOD

Close

×

RNS Number : 5179D

Midatech Pharma PLC

07 July 2016

 

 

 

 

 

Midatech Pharma PLC

("Midatech" or the "Company")

 

Grant funding received to explore Midatech's gold nanoparticle technology in immunotherapy

 

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology, immunology and other therapeutic areas, today announces that its research collaboration with Cardiff University in autoimmune therapies has received a two-year funding grant from JDRF (Juvenile Diabetes Research Foundation), for a project entitled "Gold nanoparticles coupled with selective PAMP ligands to deliver antigen specific immunotherapy" in diabetes, the commonest autoimmune disease worldwide.

 

The project, using Midatech's platform gold nanoparticle technology, will focus on developing tolerogenic mechanisms that dampen unwanted autoimmune responses to normal healthy cells in the pancreas, thus preserving the ability of these cells to continue producing insulin.  It will be led by Professor Colin Dayan, Professor of Clinical Diabetes and Metabolism, Cardiff University, and is due to start in October 2016. The total value of the grant is $477,437, of which $150,000 is due to Midatech.

 

Commenting on the grant, Dr Jim Phillips, CEO of Midatech said: "The application of gold nanoparticle technology in immunotherapy is developing rapidly and presents a significant opportunity to make a difference in the treatment of autoimmune diseases such diabetes, as well as our increasing focus on oncology indications including of brain, liver, pancreatic and ovarian cancer. The interest in applying Midatech's proprietary technology across a broad range of therapies demonstrates the potential of the platform and for the Group's pipeline."

 

Professor Colin Dayan, leading the project at Cardiff University, added: "Cardiff University looks forward to this continued collaboration using Midatech's gold nanoparticle (GNP) technology which has shown great potential to preferentially target specific immune cells, distribute rapidly to lymphoid tissues around the body, and modify the body's immune responses.  This will be an important project for autoimmune diseases generally and diabetes specifically, and we are looking forward to developing this platform combination of Midatech GNP technology, and antigen-specific immunotherapy using a wide variety of tolerogenic small partner molecules."

 

– ENDS –

 

For more information, please contact:

 

Midatech Pharma PLC

Jim Phillips, CEO

Tel: +44 (0)1235 888300

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Corporate Finance

Freddy Crossley / Atholl Tweedie / Duncan Monteith

Corporate Broking

Tom Salvesen

Tel: +44 (0)20 7886 2500

 

RBC Europe Limited (Joint Broker)

Paul Tomasic / Rupert Walford / Thomas Stockman / Laura White

Tel: +44 (0)207 653 4000

 

Consilium Strategic Communications (Financial PR)

Mary Jane Elliott / Ivar Milligan / Matthew Neal / Hendrik Thys

Tel: +44 (0)20 3709 5700

Email: midatech@consilium-comms.com

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: +1 339 970 2843

Email: chris.brinzey@westwicke.com

 

Notes for Editors

 

About Midatech Pharma PLC

Midatech is an international specialty pharmaceutical company focused on oncology and other therapeutic areas with a commercial platform and four marketed products in the US. Midatech's strategy is to develop products in-house in oncology and with partners in other indications, and to accelerate growth organically and through strategic acquisitions. The Company's R&D activities are supported by two breakthrough drug delivery technologies. The Group, listed on AIM: MTPH and Nasdaq: MTP, employs c.100 staff in four countries. For further company information see: www.midatechpharma.com

 

Forward-Looking Statement

Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements regarding the ability of Midatech to successfully test, manufacture, produce or commercialize products for diabetes or other conditions using the nanoparticle drug delivery platform, and the ability for products in development to achieve positive clinical results, and the ability to meet or achieve timelines associated with pre-clinical studies, clinical trials or regulatory submissions. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

 

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRARRMRTMBBMMIF

Close

×

RNS Number : 3425D

Obtala Resources Limited

06 July 2016

 

06 July 2016

Obtala Resources Limited

("Obtala", the "Group" or the "Company")

(AIM: OBT)

 

 

Forestry Update

 

Obtala Resources Limited (AIM:OBT), the African focused agricultural and forestry company, announces today that it has received full payment of US$500,000 from two investors, one of whom being The Chairman, as per the investment agreement announced on the 30 June 2016.

The investment proceeds will be used to further develop production capabilities within the Forestry division by building additional drying units and investing in other operating machinery.

 

 

Obtala Resources Miles Pelham – Chairman Paul Dolan – CEO www.obtalaresources.com	+44 (0)20 7099 194
ZAI Corporate Finance Limited (Nomad)                 Ray Zimmerman/Peter Trevelyan-Clark/Jamie Spotswood	+44 (0)20 7060 2220
Brandon Hill Capital  (Broker)      Jonathan Evans	+44 (0)20 3463 5000

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

STRBELLBQDFZBBK

Close

×

RNS Number : 0274D

LightwaveRF PLC

04 July 2016

 

 4 July 2016

LightwaveRF plc

(AIM: LWRF)

 

Additional distributor

 

LightwaveRF plc ("LightwaveRF" or the "Company") is the Internet of Things ("IOT") provider of the LightwaveRF platform and connected devices enabling domestic and commercial users to remotely monitor and control light, heat, power and security by smartphone, tablet or PC.  The Company is pleased to announce that it has entered an agreement with an additional UK distributor, ERA Home Security Ltd ("ERA").

 

Under the terms of the agreement ERA will become the LightwaveRF distributor into key DIY retail accounts in the UK including Kingfisher and Maplin.  ERA, which is part of Tyman Plc, recently acquired longstanding LightwaveRF customer Response Electronics who will play an active role in management of LightwaveRF's high street retailers.

 

LightwaveRF will also integrate the Response Electronics' wireless house alarms on to its platform as well as future ERA security systems.  ERA have the leading share of the UK window and door component market and will work with LightwaveRF to commercialise the previously announced, LightwaveRF patent applied  for, Smart Window system.

 

The signing of the agreement has been sealed with initial agreed orders of approximately £250,000.

 

Commenting Mike Lord, CEO of LightwaveRF, said:  "This is a significant building block in both our channels to market and technology partnerships. ERA is a large and respected company that will add significantly to the retail reach of the LightwaveRF brand. Megaman, our current distributor, will continue to focus on supplying the electrical wholesale market".

 

Will Butler, ERA's Marketing and Innovation Director added:  "The agreement with LightwaveRF differentiates the ERA product offering and strengthens our presence with OEM's, fabricators, retailers, builder's merchants, house builders and homeowners. 

 

"The broadening of our product offer with the LightwaveRF Smart Home range supports the recent Response acquisition and will further accelerate the development of our wireless alarms, electronic access and connected home capabilities".

 

For further information:

             

Contacts:
LightwaveRF plc	www.lightwaveRF.com
Mike Lord, CEO Kevin Edwards, CFO	+44 (0)  121 250 3625
WH Ireland Limited	www.wh-ireland.co.uk
Mike Coe/Ed Allsopp (Corporate Finance)	+44 (0) 117 945 3470
Jasper Berry (Institutional Sales)	+44 (0) 20 7220 1666

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

AGRDMGGNFMZGVZM

Close

×

RNS Number : 0653D

Trakm8 Holdings PLC

04 July 2016

 

4th July 2016

TRAKM8 HOLDINGS PLC

 

("Trakm8" or the "Group")

 

Allianz Awards Trakm8 Telematics Contracts

 

 

Trakm8, the AIM-listed telematics and data provider to the global market place, is pleased to announce it has been awarded two initial contracts by Allianz, the global insurance company, to supply devices with uniquely developed software to Allianz's Global Telematics business.

 

The initial supply contract comes with a launch order of 5,000 devices to start the pipe filling for Allianz Insurance telematics in China.

 

Trakm8 will provide the latest generation 5 T10 Micro self-fit telematics device, which initially will be manufactured in the Group's UK manufacturing facility. It is anticipated that manufacturing in Asia will take place as the volumes increase.

 

Trakm8, under a separate contract, will also develop specific software to meet the requirements of Allianz.

 

 

John Watkins, Executive Chairman of Trakm8 commented: 

"We are delighted to add Allianz as a customer for Trakm8's insurance telematics solutions. We have been providing telematics to insurance companies for just over two years and Allianz is the first major customer for our next generation T10 Micro product. These contracts provide additional visibility for our expectations for the current financial year and beyond."

 

 

-ends-

 

For further information please contact:

 

Trakm8 Holdings plc	+44 (0) 174 785 8444
John Watkins, Executive Chairman
James Hedges, Finance Director
finnCap (Nomad and broker)	+44 (0) 20 7220 0500
Ed Frisby / Simon Hicks – corporate finance
Joanna Scott – corporate broking
MHP Communications	+44 (0) 20 3128 8100
Reg Hoare
Jade Neal

 

 

About Trakm8

Trakm8 is a UK based Big Data company utilising telematics as its primary enabler. Through IP owned technology, over two billion miles worth of data is collected annually through its fleet management solutions to create and fine tune algorithms used to score driver behaviour, monitor vehicle health and continuously improve the security and operational efficiencies of customers' vehicles.

 

With its headquarters in Dorset and a manufacturing facility in the West Midlands, the Group supplies a number of well-known customers in the fleet management and insurance sectors across the UK and further afield including customers such as the AA, Saint Gobain, EON, Direct Line Group and Young Marmalade.

 

The Group's portfolio offers complete telematics solutions, which since the acquisition of the business and assets of DCS Systems, includes dashboard cameras that enable customers to record driving incidents and mitigate the risk from "crash to cash" accidents. This is complemented through a comprehensive hardware range, which includes a self-install unit that is one of the smallest available on the global market.

 

Recently, the Group acquired Route Monkey, significantly enhancing the Group's logistics solution which offers both route scheduling and optimisation, including routing for electric vehicles.

 

Trakm8 has been listed on the AIM market of the London Stock Exchange since 2005.

 

www.trakm8.com / @Trakm8

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

CNTUORSRNSABRAR

Close

×

RNS Number : 8811C

EU Supply PLC

01 July 2016

 

1 July 2016

EU Supply plc

("EU Supply", the "Company" or the "Group")

 

Business Alert Sales & Contract wins

 

EU Supply (LSE AIM: EUSP), the e-procurement software provider, is pleased to announce that revenues from the Group's Business Alert services in the year to date now exceed the total reported in the year ended  31 December 2015.

 

In addition, EU Supply has been awarded contracts for integrations and enhancements of its CTM™ platform from existing customers in the Nordic region. The largest of these contracts is worth around £70k with most revenues expected to be recognised in this year.

 

The Company has also received an intention to award for a smaller contract by the Norwegian Directorate for Children, Youth and Family Affairs as well as a new smaller order in Denmark increasing the Company's foothold in Norway and Denmark respectively.

 

 

FURTHER ENQUIRIES

EU Supply PLC Tel: 020 7127 4545 Thomas Beergrehn, CEO   Mattias Ström, CFO       Stockdale Securities Tel: 020 7601 6100 Tom Griffiths, David Coaten

 

A copy of this announcement is available at www.eu-supply.com.

 

Notes to Editors

EU Supply is the UK holding company of the EU Supply Group, a Sweden-based e-commerce business, which has an established, market-leading, multilingual e-procurement platform for esourcing, e-tendering and contract management, tailored for the highly regulated European public sector market.

Since 2006, the Group has invested heavily in employing specialist programmers to add functionality, legal compliance as required and security features to its Complete Tender Management™ ("CTM™") platform to ensure that the Group is ideally placed to secure new contracts with EU Member States and their Contracting Authorities. The platform is available in 16 different languages.

The Directors believe that the Group's CTM™ platform is one of the easiest to use and most functionally advanced solutions available in the market. The CTM™ platform is used by over 7,000 European public sector bodies in 9 EU/EEC Member States and has National Procurement System status in four Member States (the UK, Ireland, Norway and Lithuania).

The Company's shares were admitted to trading on AIM in November 2013. In August and September 2015, the Company raised a total of £2.061m (before expenses) through a placing of new shares and the issue of first and second tranches of Convertible Loan Notes to institutional and other investors.

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

MSCEAKKEDEAKEFF

Close

×

RNS Number : 5410C

Chamberlin PLC

29 June 2016

 

 

29 June 2016

AIM: CMH

 

CHAMBERLIN plc

("Chamberlin" or "the Company")

 

Wins

"Most Improved Supplier" Award

at

IHI Charging Systems International Conference

 

Chamberlin, the specialist castings and engineering group, is pleased to announce that its flagship foundry at Walsall was awarded "Most Improved Supplier" at a recent supplier conference held in Germany by IHI Charging Systems International, the provider of charging systems in the European turbocharger sector.

 

The award recognised Chamberlin's promotion to Category "A" supplier and makes the Company one of only two suppliers to IHI Europe Ltd ("IHI Europe") to hold this top supplier status. The re-categorisation is significant because it means that Chamberlin will now be automatically included in quoting for all future bearing housing opportunities in addition to supporting IHI Europe's technical requirements for the foreseeable future.

 

Currently, Chamberlin's Walsall operations supply over 1.6m parts to IHI Europe, worth approximately £7m per annum. The level of enquiries from IHI Europe has been increasing steadily as the foundry has improved its performance and now stands at an all-time high. 

 

Kevin Nolan, Chief Executive of Chamberlin, commenting on the award said:

 

"We are delighted to receive this award from one of our major customers, IHI Europe. Our flagship foundry at Walsall has successfully completed a period of significant transition as we have upgraded and improved processes. Walsall's promotion to Category "A" supplier to IHI Europe is significant, making the foundry one of only two suppliers to hold this top status. It also open up new opportunities, with Walsall now being automatically eligible for tending on all future bearing housing opportunities. 

 

Our recent initiative to develop Walsall's machining capability will support the foundry's ongoing growth and we look forward to building our existing strong relationship with IHI Europe."

 

Enquiries:

 

Chamberlin plc (www.chamberlin.co.uk)	T: 01922 707100
Kevin Nolan, Chief Executive
David Roberts, Finance Director
Panmure Gordon (UK) Limited	T: 020 7886 2500
(Nominated Adviser and Broker)
Adam James, Peter Steel
KTZ Communications	T: 020 3178 6378
Katie Tzouliadis, Viktoria Langley, Emma Pearson

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

NRALLFLERRITFIR

Close